塞利尼索联合维奈克拉、阿扎胞苷方案诱导治疗复发难治急性髓系白血病的疗效及安全性观察
为探讨塞利尼索联合维奈克拉（VEN）、阿扎胞苷（AZA）在复发难治急性髓系白血病（R/R AML）患者中的疗效及安全性，纳入2022年5月至2023年5月在郑州大学附属肿瘤医院接受塞利尼索联合VEN、AZA方案的12例R/R AML患者，对其临床资料进行回顾性分析。12例患者中，完全缓解（CR）5例（41.7%），CR伴血液学不完全恢复1例（8.3%），部分缓解5例（41.7%）。达CR中位时间28（16~59）d。中位无病生存期为61（15~300）d。该方案的主要不良反应为血液学不良反应，无化疗相关死亡。塞利尼索联合VEN、AZA方案是治疗R/R AML的有效治疗手段。...
Saved in:
| Published in | Zhōnghuá xuèyèxué zázhì Vol. 45; no. 8; pp. 772 - 775 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | Chinese English |
| Published |
No. 288, Nanjing road, Heping district, Tianjin
郑州大学附属肿瘤医院血液科，河南省肿瘤医院血液科，郑州 450008
14.08.2024
Editorial office of Chinese Journal of Hematology |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-2727 2707-9740 |
| DOI | 10.3760/cma.j.cn121090-20231031-00241 |
Cover
| Abstract | 为探讨塞利尼索联合维奈克拉（VEN）、阿扎胞苷（AZA）在复发难治急性髓系白血病（R/R AML）患者中的疗效及安全性，纳入2022年5月至2023年5月在郑州大学附属肿瘤医院接受塞利尼索联合VEN、AZA方案的12例R/R AML患者，对其临床资料进行回顾性分析。12例患者中，完全缓解（CR）5例（41.7%），CR伴血液学不完全恢复1例（8.3%），部分缓解5例（41.7%）。达CR中位时间28（16~59）d。中位无病生存期为61（15~300）d。该方案的主要不良反应为血液学不良反应，无化疗相关死亡。塞利尼索联合VEN、AZA方案是治疗R/R AML的有效治疗手段。 |
|---|---|
| AbstractList | 为探讨塞利尼索联合维奈克拉（VEN）、阿扎胞苷（AZA）在复发难治急性髓系白血病（R/R AML）患者中的疗效及安全性，纳入2022年5月至2023年5月在郑州大学附属肿瘤医院接受塞利尼索联合VEN、AZA方案的12例R/R AML患者，对其临床资料进行回顾性分析。12例患者中，完全缓解（CR）5例（41.7%），CR伴血液学不完全恢复1例（8.3%），部分缓解5例（41.7%）。达CR中位时间28（16~59）d。中位无病生存期为61（15~300）d。该方案的主要不良反应为血液学不良反应，无化疗相关死亡。塞利尼索联合VEN、AZA方案是治疗R/R AML的有效治疗手段。 为探讨塞利尼索联合维奈克拉（VEN）、阿扎胞苷（AZA）在复发难治急性髓系白血病（R/R AML）患者中的疗效及安全性，纳入2022年5月至2023年5月在郑州大学附属肿瘤医院接受塞利尼索联合VEN、AZA方案的12例R/R AML患者，对其临床资料进行回顾性分析。12例患者中，完全缓解（CR）5例（41.7％），CR伴血液学不完全恢复1例（8.3％），部分缓解5例（41.7％）。达CR中位时间28（16～59）d。中位无病生存期为61（15～300）d。该方案的主要不良反应为血液学不良反应，无化疗相关死亡。塞利尼索联合VEN、AZA方案是治疗R/R AML的有效治疗手段。 |
| Abstract_FL | To determine the efficacy and safety of selinexor combined with venetoclax (VEN) and azactitidine (AZA) for patients with relapsed and/or refractory acute myeloid leukemia (R/R AML) . Twelve patients with R/R AML treated with selinexor plus VEN and AZA in the Affiliated Cancer Hospital of Zhengzhou University from May 2022 to May 2023 were included. Their clinical data were retrospectively analyzed. Among the 12 R/R AML patients, 5 (41.7%) achieved complete remission (CR) , 1 (8.3%) achieved CR with incomplete hematological recovery, and 5 (41.7%) achieved partial remission. The median time to reach CR was 28 (16-59) days. The median PFS was 61 (15-300) days. The main adverse event of the regimen was hematological toxicity. No chemotherapy-related deaths were observed. The combination of selinexor plus VEN and AZA is an effective treatment for R/R AML patients. |
| Author | 房佰俊 崔玉山 王耀美 刘丽娜 向谱 梁利杰 刘玉章 李以冉 |
| AuthorAffiliation | 郑州大学附属肿瘤医院血液科，河南省肿瘤医院血液科，郑州 450008 |
| AuthorAffiliation_xml | – name: 郑州大学附属肿瘤医院血液科，河南省肿瘤医院血液科，郑州 450008 – name: 郑州大学附属肿瘤医院血液科，河南省肿瘤医院血液科，郑州 450008 Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China |
| Author_FL | Liu Yuzhang Xiang Pu Li Yiran Liang Lijie Wang Yaomei Fang Baijun Liu Li'na Cui Yushan |
| Author_FL_xml | – sequence: 1 fullname: Liu Li'na – sequence: 2 fullname: Cui Yushan – sequence: 3 fullname: Liu Yuzhang – sequence: 4 fullname: Wang Yaomei – sequence: 5 fullname: Xiang Pu – sequence: 6 fullname: Liang Lijie – sequence: 7 fullname: Li Yiran – sequence: 8 fullname: Fang Baijun |
| Author_xml | – sequence: 1 fullname: 刘丽娜 – sequence: 2 fullname: 崔玉山 – sequence: 3 fullname: 刘玉章 – sequence: 4 fullname: 王耀美 – sequence: 5 fullname: 向谱 – sequence: 6 fullname: 梁利杰 – sequence: 7 fullname: 李以冉 – sequence: 8 fullname: 房佰俊 |
| BookMark | eNpVkV1LG0EUhgexaLT-DL3beGZmZ2f3SorYVhC80etldmdXE8wmJPWrvYnVwMbgF_Wj9cISUVQE4xeUElt_jMzu5l-4oDdeHV7Ow8M5vH2oOygGHkKDGLKUGzDsFkQ2n3UDTDBYoBEgFAPFGgDRcRfKEA5cs7gO3SgDhFGNcMJ7UV-lkgfQCWC9B_VSiwLnhGXQN9U8UuGFun6I74-TlV21Hcbte3UaqlojatSfqiudn49RfTNZPUoaf6L9v1EzTFo3qvUQ3bbj_QN1sqG2djqH_9MYVU-j6lnn8kd8145__Uua1figFh-upVi0F6qtdXVVV7XzlEnOvqvW7_fonS_mKt7A6-xH0x_HpkY_axOTn8ZHP0xoJcy4qTGDmRjAEi7mTOdgSo9gx09_86hpOoaU3HUcSR0LfMP0uRDSl7qkBjG4lJak_WjkxVuadwqedL3gS1nM2aVyriDKy3ZR5Oy3myA3a88UF2yMGWXMwKlh6MWwKAJfBDN2vjhfDtKb7a-zS8tLaQk6mAAmfQZMA6pH |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. 2024年版权归中华医学会所有 Copyright © 2024 by Chinese Medical Association 2024 |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: 2024年版权归中华医学会所有 Copyright © 2024 by Chinese Medical Association 2024 |
| DBID | 2B. 4A8 92I 93N PSX TCJ 5PM |
| DOI | 10.3760/cma.j.cn121090-20231031-00241 |
| DatabaseName | Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitle_FL | The clinical safety and efficacy of selinexor combined with venetoclax and azactitidine induction therapy in relapsed and refractory acute myeloid leukemia |
| EISSN | 2707-9740 |
| EndPage | 775 |
| ExternalDocumentID | PMC11535561 zhxyx202408008 |
| GrantInformation_xml | – fundername: 国家自然科学基金; 中原英才计划资助项目; 河南省高等学校重点科研项目计划 funderid: (82370143); (214200510023); (22A320061) |
| GroupedDBID | --- -05 2B. 4A8 92F 92I 93N ABJNI ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CW9 F5P OK1 PSX RPM TCJ TGQ U1G U5O 5PM |
| ID | FETCH-LOGICAL-p1578-56581009ac1754708de21bf253e388b6dd7cbbd3b90f68f7aadfd4d36267dd9d3 |
| ISSN | 0253-2727 |
| IngestDate | Thu Aug 21 18:35:42 EDT 2025 Thu May 29 04:05:49 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 8 |
| Language | Chinese English |
| License | This work is licensed under a Creative Commons Attribution 3.0 License. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-p1578-56581009ac1754708de21bf253e388b6dd7cbbd3b90f68f7aadfd4d36267dd9d3 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11535561 |
| PMID | 39307725 |
| PageCount | 4 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11535561 wanfang_journals_zhxyx202408008 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-14 |
| PublicationDateYYYYMMDD | 2024-08-14 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-14 day: 14 |
| PublicationDecade | 2020 |
| PublicationPlace | No. 288, Nanjing road, Heping district, Tianjin |
| PublicationPlace_xml | – name: No. 288, Nanjing road, Heping district, Tianjin |
| PublicationTitle | Zhōnghuá xuèyèxué zázhì |
| PublicationTitle_FL | Chinese Journal of Hematology |
| PublicationYear | 2024 |
| Publisher | 郑州大学附属肿瘤医院血液科，河南省肿瘤医院血液科，郑州 450008 Editorial office of Chinese Journal of Hematology |
| Publisher_xml | – name: 郑州大学附属肿瘤医院血液科，河南省肿瘤医院血液科，郑州 450008 – name: Editorial office of Chinese Journal of Hematology |
| SSID | ssj0042014 ssib051368330 ssib001103535 ssib058574913 |
| Score | 2.4230995 |
| Snippet | 为探讨塞利尼索联合维奈克拉（VEN）、阿扎胞苷（AZA）在复发难治急性髓系白血病（R/R AML）患者中的疗效及安全性，纳入2022年5月至2023年5月在郑州大学附属肿瘤医院接受塞... |
| SourceID | pubmedcentral wanfang |
| SourceType | Open Access Repository Aggregation Database |
| StartPage | 772 |
| SubjectTerms | 短篇论著 |
| Title | 塞利尼索联合维奈克拉、阿扎胞苷方案诱导治疗复发难治急性髓系白血病的疗效及安全性观察 |
| URI | https://d.wanfangdata.com.cn/periodical/zhxyx202408008 https://pubmed.ncbi.nlm.nih.gov/PMC11535561 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2707-9740 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0042014 issn: 0253-2727 databaseCode: RPM dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3batRANEhF8UUUFe_64DymJpnZzMxjspulCPpUoW8ll41VcBWtWOtLqxa2Fq3ivQ9KxVJFsF4KIvXyG75Ldrd_4TmT6W5axRtCGaY5Z859Z84ZJhPDOBRC0WNHcWqm0o1MJqQwIxmFJo1hceeOELF66_3oMbfvODsyUBpY1_O1cGrpwnDUG4_-9L2Sf_EqPAO_4luyf-HZDlF4AH3wL7TgYWj_yMckKBHPJjLAjhDEk9jxLeKXScCJz4jnkEBAtkgkQ5C0EA1BPkJxuBqIw-HPJ4GLrQA6FM9AwMBAEimIX1UgSUSgCFLFVCCyzxEkXeJL7IA8SBCEqRLfViyqSh5AcJAvcAdkyRUIMtmK4l4lMuflET8oILsoBgipOxxxPJ9IqrSgKwQl8SuKqY1o-ISjRtjxiGAFptB2VK4S4SkxAqWyMoInCrwEtsLRWshVZyBJwIgPCLn8FW0ZLQDIr1TAgRXiuYpvRZMCY8rO8q9dBzbO6fmKHkghy0UU8JZUaogVWcG4vv0TKh0UjobyrC5KDvGV3yxtJzC2CIpbPw7DvWy7u_WLFkd_K1-Cs_NoA895vKCeRB8IpgXTweGouOEolqdAoqwcppDz0FxrL45kkZcKGtGJG6qtjC4EhLIKzf_F4kcF8-iHQgSz18Ji6ZSoCZMLL67s-UWlegYThWWa55-L0hkfz7_dszaZwONiMAPEp8PeU71xHW_akxbMP1gRUdvE7NbuZlGds62jQyOXRhx1daC6hWC9A_mGtWYfEZJuWuoWKiWbuoJ2C3mo4TlT5wfynJJBmq4uwlvRcqNBtISHfynfj0e9N1wM62lYP1HIovu3GJt1-XvQy-eyrca60aFtxuVs9nHWeJG9_thafNoev5vdarSWFrO5RjYx1Zya_DY2vvzwS3PyZvvq4_bU--b9D83ZRnvhTbbwsfl2qXX_QfbsRjZ9e3nmM_zbHJtrjs0vv7zTerfUevSpPTvWejDRmrkGaM17jWz6evZqMpt4Djjt-SvZwpPtxvFq0F_uM_VHYcyzNmQXJhSgwobCMIyh8GHcEknNsaMUDFOjQkRukvA4ihIaSSt1RcrDMEkTluCtWzxJZEJ3GD31M_XaTuNgidMIDB0nNhMsrkGlJi1Wc1NqhWmtxOQuQ6wy3uDZ_AKgQbySfzWkfnJIXc0P9TXFDw7vMg5oOw_q9eL84OrA2P1bjD3Gpu6Pfq_RM3zuQm0fVEDD0X4VTN8BR8QYeA |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%A1%9E%E5%88%A9%E5%B0%BC%E7%B4%A2%E8%81%94%E5%90%88%E7%BB%B4%E5%A5%88%E5%85%8B%E6%8B%89%E3%80%81%E9%98%BF%E6%89%8E%E8%83%9E%E8%8B%B7%E6%96%B9%E6%A1%88%E8%AF%B1%E5%AF%BC%E6%B2%BB%E7%96%97%E5%A4%8D%E5%8F%91%E9%9A%BE%E6%B2%BB%E6%80%A5%E6%80%A7%E9%AB%93%E7%B3%BB%E7%99%BD%E8%A1%80%E7%97%85%E7%9A%84%E7%96%97%E6%95%88%E5%8F%8A%E5%AE%89%E5%85%A8%E6%80%A7%E8%A7%82%E5%AF%9F&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E5%88%98%E4%B8%BD%E5%A8%9C&rft.au=%E5%B4%94%E7%8E%89%E5%B1%B1&rft.au=%E5%88%98%E7%8E%89%E7%AB%A0&rft.au=%E7%8E%8B%E8%80%80%E7%BE%8E&rft.date=2024-08-14&rft.pub=%E9%83%91%E5%B7%9E%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%A1%80%E6%B6%B2%E7%A7%91%EF%BC%8C%E6%B2%B3%E5%8D%97%E7%9C%81%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E8%A1%80%E6%B6%B2%E7%A7%91%EF%BC%8C%E9%83%91%E5%B7%9E%E3%80%80450008&rft.issn=0253-2727&rft.volume=45&rft.issue=8&rft.spage=772&rft.epage=775&rft_id=info:doi/10.3760%2Fcma.j.cn121090-20231031-00241&rft.externalDocID=zhxyx202408008 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg |